Attorneys for plaintiffs alleging that labeling fails to warn about potential risks concerning prenatal use of Tylenol didn’t help their cause by failing to respond to a judge’s deadline for showing cause that their complaint shouldn’t be dismissed.
Marketers of other drugs with acetaminophen or other active ingredients available under a Food and Drug Administration OTC monograph may want to note, though, that dismissal of the complaint against Kenvue Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?